Material Safety Data Sheet Section 1. Identification of the substance Product Name: Methyl 3-bromopicolinate Synonyms: Section 2. Hazards identification Harmful by inhalation, in contact with skin, and if swallowed. Section 3. Composition/information on ingredients. Ingredient name: Methyl 3-bromopicolinate CAS number: 53636-56-9 Section 4. First aid measures Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing contaminated clothing and shoes. If irritation persists, seek medical attention. Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical attention. Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention. Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention. Section 5. Fire fighting measures In the event of a fire involving this material, alone or in combination with other materials, use dry powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus should be worn. Section 6. Accidental release measures Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national standards. Respiratory precaution: Wear approved mask/respirator Hand precaution: Wear suitable gloves/gauntlets Skin protection: Wear suitable protective clothing Eye protection: Wear suitable eye protection Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container for disposal. See section 12. Environmental precautions: Do not allow material to enter drains or water courses. Section 7. Handling and storage Handling: This product should be handled only by, or under the close supervision of, those properly qualified in the handling and use of potentially hazardous chemicals, who should take into account the fire, health and chemical hazard data given on this sheet. Store in closed vessels. Storage: Section 8. Exposure Controls / Personal protection Engineering Controls: Use only in a chemical fume hood. Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles. General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse. Section 9. Physical and chemical properties Appearance: Not specified Boiling point: No data No data Melting point: Flash point: No data Density: No data Molecular formula: C7H6BrNO2 Molecular weight: 216.0 Section 10. Stability and reactivity Conditions to avoid: Heat, flames and sparks. Materials to avoid: Oxidizing agents. Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide. Section 11. Toxicological information No data. Section 12. Ecological information No data. Section 13. Disposal consideration Arrange disposal as special waste, by licensed disposal company, in consultation with local waste disposal authority, in accordance with national and regional regulations. Section 14. Transportation information Non-harzardous for air and ground transportation. Section 15. Regulatory information No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302, or have known CAS numbers that exceed the threshold reporting levels established by SARA Title III, Section 313.
发现和SAR的第一个临床阶段蛋白激酶CK2抑制剂5-(3-氯苯基氨基)苯并[ c ] [2,6]萘吡啶-8-羧酸(CX-4945)
摘要:
本文中,我们对CX-4945(25n)的发现进行了编年史,CX-4945是蛋白激酶CK2的一流的,口服可生物利用的ATP竞争性抑制剂,在癌症的临床试验中得到了证实。CK2长期以来一直被认为是主要的癌症药物靶标,因为CK2的失调和过度表达在促进癌症的生存和抗凋亡途径中起着重要的作用。这些生物学特性以及CK2的小ATP结合位点对选择性抑制剂设计的适用性,使我们开发出了新型的癌症治疗剂。导致25n(K i = 0.38 nM)的最优化是通过分子建模指导的,这表明25n的强结合由疏水相互作用,与Lys68形成的离子桥以及与铰链区的氢键结合而成。发现25n具有高度选择性,可跨物种口服生物利用(20-51%),并且在异种移植模型中有效。25n的发现将首次使CK2在人类中具有治疗靶向性。
[EN] ARGINASE INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS D'ARGINASE ET PROCÉDÉS D'UTILISATION
申请人:MERCK SHARP & DOHME
公开号:WO2019177873A1
公开(公告)日:2019-09-19
Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as arginase inhibitors and can be useful in preventing, treating or acting as a remedial agent for arginase-related diseases.
[EN] INSECTICIDAL METHODS USING NITROGEN-CONTAINING HETEROAROMATIC COMPOUNDS<br/>[FR] PROCÉDÉS INSECTICIDES UTILISANT DES COMPOSÉS HÉTÉROAROMATIQUES CONTENANT DE L'AZOTE
申请人:BASF SE
公开号:WO2011064188A1
公开(公告)日:2011-06-03
Insectical methods using nitrogen containing heteroaromatic compounds The present invention relates to new insecticidal methods of using nitrogen-containing heteroaromatic compounds of the formula (I), wherein A, E, G, M, W, Y, X, R1 and R2 are defined as in the description, and to their enantiomers, diastereomers and agriculturally and veterinary acceptable salts. The present invention relates to methods of administering and applying such Pyridine compounds of formula I for insecticidal use and purposes in agriculture and in the veterinary field. The invention relates also to new derivatives of Pyridine compounds of formula I.
1-(2-PHENOXYMETHYLHETEROARYL)PIPERIDINE AND PIPERAZINE COMPOUNDS
申请人:Stangeland Eric L.
公开号:US20110230495A1
公开(公告)日:2011-09-22
The invention relates to compounds of formula I:
where X, HAr, a, and R
1
through R
6
are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.
[EN] COMPOUNDS AND METHODS<br/>[FR] COMPOSÉS ET MÉTHODES
申请人:TEMPERO PHARMACEUTICALS INC
公开号:WO2013019682A1
公开(公告)日:2013-02-07
The present invention relates to novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORy.